1. An observational study on prevalence of latent tuberculosis infection and outcome of 3HP treatment in patients under hemodialysis in Taiwan
- Author
-
Chia-An Chou, Chien-Hsing Wu, Lo-Hsin Dai, Jien-Wei Liu, Hsuan-An Su, Chien-Te Lee, and Chih-Chao Yang
- Subjects
Male ,medicine.medical_specialty ,Medicine (General) ,Tuberculosis ,medicine.medical_treatment ,Population ,Antitubercular Agents ,Taiwan ,Interferon-gamma release assay (IGRA) ,12-Week weekly rifapentine plus isoniazid (3HP) ,03 medical and health sciences ,0302 clinical medicine ,R5-920 ,Latent Tuberculosis ,Renal Dialysis ,Internal medicine ,Isoniazid ,Prevalence ,medicine ,Humans ,education ,Dialysis ,education.field_of_study ,Latent tuberculosis ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Rifapentine ,End-stage renal disease (ESRD) ,Discontinuation ,Latent tuberculosis infection (LTBI) ,030220 oncology & carcinogenesis ,Hemodialysis ,Drug Therapy, Combination ,030211 gastroenterology & hepatology ,business ,Adverse drug reaction ,Follow-Up Studies ,medicine.drug - Abstract
Background: Identification and treatment for latent tuberculosis infection (LTBI) are of great epidemiological importance of controlling tuberculosis (TB) worldwide. Identification in high-risk population on dialysis and treatment with 12-week weekly rifapentine plus isoniazid (3HP) help improve prevention outcomes effectively. Methods: We conducted a single-center, nonrandomized follow-up study on end-stage renal disease patients on hemodialysis. The interferon-gamma release assay (IGRA) was used for the diagnosis of LTBI. Participants were treated with 3HP, and treatment responses were recorded and analyzed. Results: A total of 123 of the 641 patients showed positive IGRA results. The male sex, age >60 years, low serum albumin level ( 10.2 mg/dL) were associated with IGRA positivity. Seventy-five patients were treated with 3HP, with a completion rate of 66.67%. The male sex, albumin level >4.0 g/dL, and absence of adverse drug reaction were associated with increased completion rates. Adverse drug reactions included dizziness, fatigue, nausea and vomiting, fever, and hypertension. Conclusion: Risk factors for LTBI in dialysis patients were identified to prioritize LTBI screening and initiate early treatment. The completion rate in dialysis patients were approximately 2 of 3 patients with mild adverse drug reaction, leading to discontinuation of the treatment.
- Published
- 2021